Search Results
May 15, 2026, 08:30 ET Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
multi‑modal profiling, as biomarker detection required diverse methodologies, including Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), Immunohistochemistry (IHC) and combinations of these approaches.Beyond molecular identification, the study also demonstrated the effectiveness
More news about: Caris Life Sciences
May 11, 2026, 12:15 ET Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors and includes quantitative reporting of TMB.About
More news about: Caris Life Sciences
Apr 30, 2026, 06:30 ET PBF Energy Announces First Quarter 2026 Results, Declares Dividend of $0.275 per Share and Update on Restart of Martinez Refinery
Dated Brent less WTS (sour)$ 10.21
More news about: PBF Energy Inc.
Apr 29, 2026, 16:15 ET NWPX Infrastructure Announces First Quarter 2026 Financial Results
mix.WTS gross profit increased 42.3% to $17.3 million, or 18.5% of WTS net sales, from $12.2 million, or 15.5% of WTS net sales, in the first quarter of 2025 due to increased volume, including related operational efficiency gains, and favorable changes in product mix.WTS backlog was
More news about: NWPX Infrastructure, Inc.
Apr 29, 2026, 08:30 ET Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.GBM is the most common
More news about: Caris Life Sciences
Apr 15, 2026, 08:30 ET Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
Every patient whose tumor specimen is sent to Caris receives profiling through Whole Exome Sequencing (WES) of DNA, Whole Transcriptome Sequencing (WTS) of RNA and immunohistochemistry (IHC) analysis of proteins, covering more than 23,000 genes.A proprietary trial-matching platform then cross-references
More news about: Caris Life Sciences
Apr 08, 2026, 08:30 ET Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, which utilize Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate greater biological understanding and more actionable insights for physicians and patients.NSCLC is the most common
More news about: Caris Life Sciences
Apr 02, 2026, 08:30 ET Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia
More news about: Caris Life Sciences
Mar 26, 2026, 08:30 ET Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
proprietary CodeAI™ platform, now exceeding over half a million patients tested with Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS), H&E and IHC images with longitudinal follow-up clinical data. The novel Caris signatures for breast cancer and non-small cell lung cancer (NSCLC)
More news about: Caris Life Sciences
Mar 25, 2026, 08:30 ET Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects
More news about: Caris Life Sciences
Mar 20, 2026, 08:30 ET Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
additional cost. Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.About Caris Life Sciences Caris
More news about: Caris Life Sciences
Mar 16, 2026, 08:30 ET Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer
CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.By harnessing AI across
More news about: Caris Life Sciences
Mar 11, 2026, 08:30 ET Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
Caris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used to generate the results being presented. The studies, including one oral presentation and four posters,
More news about: Caris Life Sciences
Mar 09, 2026, 08:30 ET Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer
CodeAI™ platform, enabling the creation of Caris AI Insights, an engine that utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate deeper biological understanding and more actionable insights for clinicians and researchers.By harnessing AI across
More news about: Caris Life Sciences
Mar 09, 2026, 07:00 ET HORIZON PETROLEUM APPOINTS TREVOR WILLIAMS TO THE BOARD OF DIRECTORS
wastewater management, giving him a robust, practical approach to leadership.Over the past twenty years, Trevor has been instrumental in building WTS, a wastewater management company that focuses on wastewater disposal solutions for remote worksites. During the company's development, Trevor gained
More news about: Horizon Petroleum Ltd.
Feb 25, 2026, 16:15 ET NWPX Infrastructure Announces Fourth Quarter and Full Year 2025 Financial Results
resulting from changes in project timing.WTS gross profit increased 20.6% to $17.8 million, or 21.2% of WTS net sales, from $14.8 million, or 17.9% of WTS net sales, in the fourth quarter of 2024 primarily due to increased selling prices.WTS backlog was $234 million as of December 31, 2025
More news about: NWPX Infrastructure, Inc.
Feb 24, 2026, 08:30 ET Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug
for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.About Caris Life SciencesCaris
More news about: Caris Life Sciences
Feb 12, 2026, 06:30 ET PBF Energy Reports Fourth Quarter and Full Year 2025 Results, Declares Dividend of $0.275 per Share
Dated Brent less WTS (sour)$ 5.26
More news about: PBF Energy Inc.
Jan 29, 2026, 16:46 ET NWPX Infrastructure Announces Strategic Leadership Promotions
Stokes has been promoted to Senior Vice President and WTS Group President. He will continue to have commercial and operating responsibility for the WTS segment, which includes all sales, engineering, quality, and production for the Company's WTS plants in North America. His broadened responsibilities
More news about: NWPX Infrastructure, Inc.
Jan 28, 2026, 08:30 ET Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
real-world clinical outcomes with Caris's comprehensive molecular profiling, including whole exome sequencing (WES) and whole transcriptome sequencing (WTS), the study enables a population-level analysis of resistance pathways across DNA, RNA and protein expression."In this large real-world analysis,
More news about: Caris Life Sciences
Jan 13, 2026, 12:55 ET Nicole Arbour to Star in We The Studios' First International Romantic Comedy Reality Series
from 15 plus years in Hollywood. The mission is to deliver bold and inspiring content, free from agendas, profanity, alcohol, and inappropriate themes. WTS release new episodes weekly, providing parents and children with high-quality entertainment they can enjoy together. Join us as we lead a cultural shift
More news about: We The Studios
Nov 17, 2025, 13:03 ET TipRanks partners with KB Securities: South Korea's largest financial institution
Scores — will be sequentially introduced to KB Securities' two primary trading platforms: the MTS ('Mobile Trading System'), named 'KB M-able' and the WTS ('Web Trading System'), called 'M-able Wide.' TipRanks Co-founder and CEO Uri Gruenbaum said, "Korea is an innovative market where
More news about: TipRanks
Oct 30, 2025, 06:30 ET PBF Energy Announces Third Quarter 2025 Results and Declares Dividend of $0.275 per Share
Dated Brent less WTS (sour)
More news about: PBF Energy Inc.
Oct 29, 2025, 16:15 ET NWPX Infrastructure, Inc. Announces Third Quarter 2025 Financial Results
WTS gross profit increased 33.0% to $22.1 million, or 21.3% of WTS net sales, from $16.6 million, or 19.4% of WTS net sales, in the third quarter of 2024 due to increased volume, including related operational efficiency gains, and changes in product mix. WTS backlog
More news about: NWPX Infrastructure, Inc.
Oct 14, 2025, 08:30 ET Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
Paper," one mini-oral and four poster presentations. The studies highlight Caris' continued leadership in applying next-generation sequencing (WES and WTS), immunohistochemistry (IHC) and real-world clinico-genomic data to uncover actionable insights. Tumor types represented include colorectal, gastric,
More news about: Caris Life Sciences